Abstract
Introduction: Arginine vasopressin (AVP) plays a prominent role in water retention and vasoconstriction and is inappropriately elevated in many patients with both acute and chronic heart failure (HF). Acute decompensated HF (ADHF) is characterized primarily by congestion. Conventional diuretics alone are often ineffective in relieving congestion in ADHF. Conivaptan (CNV), a novel V1A- and V2-AVP antagonist, would be expected to produce clinical improvement in ADHF. Hypothesis: CNV will alleviate signs and symptoms of congestion in patients with ADHF.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
